RANI: 1Q:24 Results
By John Vandermosten, CFA NASDAQ:RANI READ THE FULL RANI RESEARCH REPORT Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) reported first quarter 2024 results on May 6th, 2024. However, there has been...
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
2.62 | |
2.71 | |
- | |
2.755 | |
2.55 | |
1.82-8.75 | |
143 M | |
29 290 K | |
0 | |
-0.26 | |
0.169 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
By John Vandermosten, CFA NASDAQ:RANI READ THE FULL RANI RESEARCH REPORT Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) reported first quarter 2024 results on May 6th, 2024. However, there has been...
By John Vandermosten, CFA NASDAQ:RANI READ THE FULL RANI RESEARCH REPORT We are initiating coverage of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) with a target price of $12.00 per share. This v...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: